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FOR INHIBITORS OF 
STREPTOCOCCUS PYOGENES
SORTASE A




Antimicrobial resistance resulting in ineffective treatment of infectious diseases is 
an increasing global problem, particularly in infections with pathogenic bacteria. In 
some bacteria, such as Streptococcus pyogenes, the pathogenicity is strongly linked to 
the attachment of virulence factors. Their attachment to the cellular membrane is 
a transpeptidation reaction, catalyzed by sortase enzymes. As such, sortases pose 
an interesting target for the development of new antivirulence strategies that could 
yield novel antimicrobial drugs. Using the substitution-oriented fragment screening 
(SOS) approach, we discovered a potent and specific inhibitor (C10) of sortase A from 
S. pyogenes. The inhibitor C10 showed high specificity towards S. pyogenes sortase 
A, with an IC50 value of 10 μM and a Kd of 60 µM. We envision that this inhibitor 
could be employed as a starting point for further exploration of sortase’s potential 
as therapeutic target for antimicrobial drug development.
Keywords: Streptococcus pyogenes; sortase A; antivirulence; inhibitor; substitution-
oriented screening.
Abbreviations
Sp-SrtA: Streptococcus pyogenes sortase A
Sa-SrtA: Staphylococcus aureus sortase A
SOS: Substitution-oriented fragment screening
MST: Microscale thermophoresis
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INTRODUCTION
Streptococcus pyogenes is a pathogenic Gram-positive bacterium, harboring the 
Lancefi eld group A antigen. S. pyogenes can cause infections that are benign and self-
healing, e.g. pharyngitis, skin infections and impetigo. However, some S. pyogenes
strains are equipped with surface virulence molecules that enable the bacteria 
to invade the organism more deeply and spread to various organs unnoticed. 
This can lead to life-threatening diseases such as necrotizing fasciitis, septicemia 
or toxic shock syndrome [1,2]. The worldwide mortality rate caused by severe S. 
pyogenes infections exceeds 500,000 deaths per year [3]. Unsurprisingly, this high 
mortality is caused by an increasing resistance of this microorganism to currently 
used antibiotics [4].
Group A streptococci can be classifi ed based on the type of M protein they express. 
M proteins are virulence factors, and as such they are associated with disease 
severity and infectivity [5]. In fact, many of the proteins expressed on the surface of 
S. pyogenes are virulence factors, essential for adhesion, colonization, internalization 
and biofi lm formation. [6]. Some of these virulence factors are attached to the cell 
wall through a transpeptidation reaction catalyzed by the enzyme sortase A (SrtA) 
[7,8].
SrtA belongs to a class of enzymes displayed on the surface of Gram-positive 
bacteria, where they play a pivotal role in the pathogenicity of the bacterium. All 
proteins to be processed by SrtA bear a sorting motif of fi ve amino acids at the 
C-terminus followed by a hydrophobic domain and a positively charged tail. Once 
the motif is recognized by the SrtA enzyme, it cleaves the peptide bond between 
the last two residues and forms an acyl-enzyme intermediate linked by a thioester 
bond between the carboxyl group of the motif and the cysteine located in the active 
site of the enzyme. Next, lipid II performs a nucleophilic attack on the acyl-enzyme 
intermediate, which results in the formation of a new peptide bond between the 
C-terminus of the surface protein and the N-terminus of lipid II. As a result, the 
surface protein is covalently anchored to the cell wall of bacteria [9].
To demonstrate the role of SrtA in the development of infections, a number of 
studies using Gram-positive srtA knockout strains was performed in mouse models 
for infectious disease. Indeed, mice infected with Staphylococcus aureus srtA deletion 
mutants did not develop infections due to the absence of virulence factors. 
Interestingly, deletion of srtA was not lethal to the bacteria, nor did it lead to growth 
defects, suggesting that this enzyme is not essential to sustain life processes of S. 
2
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aureus [10]. A study performed with S. pyogenes showed that a srtA knockout strain 
had become susceptible to phagocytic killing [11]. Hence, our hypothesis is that a 
small molecule inhibitor of sortase A from S. pyogenes (Sp-SrtA) could function as an 
anti-infective agent. In contrast to antibiotics, our strategy relies on the inhibition of 
bacterial virulence thus making pathogens more susceptible to immune clearance by 
the host [12]. Since Sp-SrtA is not essential for the basic life processes of S. pyogenes, 
inhibition of this enzyme is less likely to lead to the development of antimicrobial 
resistance [13,14].
The development of inhibitors by screening natural products and small molecules 
or by designing inhibitors in silico has so far targeted sortase’s catalytic cysteine 
residue. Until now, several inhibitors of sortase A from S. aureus (Sa-SrtA) have been 
identified, with the best inhibitor displaying a half maximal inhibitory concentration 
(IC50) of 200 nM [13,15–17]. The focus of the current study, however, is on the 
inhibition of Sp-SrtA; to our knowledge, only one small molecule inhibitor of this 
enzyme has been described. The reported triazolo-thiadiazole-based molecule 
showed a tenfold higher inhibitory effect on Sp-SrtA than on Sa-SrtA [18].
In the current study, we applied substitution-oriented fragment screening (SOS) [19–
21], a rational approach, employed by an in vitro fluorometric assay. Our approach 
was to develop an Sp-SrtAΔN81-selective inhibitor that would interact with amino 
acids located near the catalytic center of the enzyme. Based on the knowledge 
of currently available inhibitors of Sa-SrtAΔN24 activity and the 3D structure of 
Sp-SrtAΔN81 (Protein data bank (PDB) IDs: 3FN5 and 3FN7), we designed a SOS 
library of nitrogen-containing aromatic compounds targeting the active site. After 
screening, we found an inhibitor for Sp-SrtAΔN81 with an IC50 of 10 µM and a Kd 
of 60 µM; this compound is specific, as it does not inhibit Sa-SrtAΔN59.
RESULTS AND DISCUSSION
Design and screening of the compound library for enzymatic inhibition
In previously reported studies on the homologous Sa-SrtAΔN24, an indole derivative 
showed promising inhibitory effects on this enzyme [22]. Based on these findings, 
we designed a compound collection of indole derivatives.
Using the 3D structure of S. pyogenes sortase A (PDB ID: 3FN7), we performed 
molecular modeling studies targeting the active site of the enzyme [23]. By 
measuring the distances between important active site residues of Sp-SrtAΔN81, we 
confirmed indoles to be the best candidate scaffold with regard to its structural and 
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in general favorable physicochemical properties. A focused library was assembled, 
consisting of 92 nitrogen-containing aromatic compounds including 50 indoles and 
42 other heterocycles with diff erent substitution patterns. The compounds were 
selected to have various hydrogen bond donor and acceptor groups targeting the 
amino acid residues located at the active site (Figure 1). A full list of the compounds 
from the library can be found in the supporting PDF fi le.
FIGURE 1. Initial modeling of the binding position of inhibitors based on the 3D structure of 
Sp-SrtAΔN81 (PDB ID: 3FN7).
A fl uorometric assay monitoring the hydrolysis of an internally quenched Abz-
LPETA-Dap(Dnp) substrate analogue for sortase A from S. pyogenes was used for 
the inhibitory screening. The screening results for the most active compounds from 
the SOS library at two diff erent concentrations are presented in Figure 2.
To calculate the potency of inhibition, an end-point analysis of the formation of 
fl uorescent product was performed. For each run, the positive control (no inhibitor), 
was determined as 100% residual activity. After the fi rst screening at a concentration 
of 100 µM, eight compounds were found to exhibit an inhibition of SrtA activity 
greater than 50% (Figure 2, 3). The residual activity for compound D9 was set to 
0% as the slope of the reaction was negative. For the selection of the most potent 
inhibitors, the compound library was screened at a concentration of 10 µM. The 
most potent inhibitor C10, (2-amino-6-chloro-1H-indol-3-yl)(morpholino)methanone, 
showed a good correlation in inhibition at 100 µM and 10 µM. In addition, C10
presented better solubility properties compared to the other compound hits. After 
corroborating its purity by LC-MS (Supplementary Figure S1), C10 was selected for 
2
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further characterization and used as a lead compound for a structure-activity 
relationship (SAR) analysis. The remaining seven compound hits (Figure 3) were 
not studied further, though they may form an interesting starting point for future 
research.
FIGURE 2. Screening the SOS library of SrtA inhibitors at a concentration of 100 µM (white bars) 
and 10 µM (black bars). The eight depicted compounds triggered a more than 50% decrease in 
sortase activity compared to the positive (untreated) control (PC).
Selectivity profi le and kinetics. The IC50 of the C10 inhibitor against Sp-SrtAΔN81 
was determined to be 10 µM (Figure 4). Importantly, compound C10 was found to be 
specifi c for Sp-SrtAΔN81 as it did not inhibit the homologous Sa-SrtAΔN59 (Figure 
4A). This fi nding strengthened our initial modeling studies, as they were specifi cally 
directed towards the blocking of the active site of Sp-SrtAΔN81 and not Sa-SrtAΔN59. 
Although the overall structures of Sp-SrtAΔN81 and Sa-SrtAΔN59 are very similar, 
there are some important diff erences in the arrangement of Sp-SrtAΔN81’s catalytic 
triad that lead to distinct activities and substrate specifi cities for these enzymes 
[23]. This diff erence was highlighted in a study by Zhang et al, in which, surprisingly, 
a small molecule inhibitor identifi ed on Sa-SrtAΔN59 exhibited a 10-fold lower IC50 
towards Sp-SrtAΔN81 [18]. Lee et al. prepared a series of synthesized analogs of 
natural products with indole pharmacophores, which showed inhibitory activity 
towards Sa-SrtA. Here, the indole moiety only interacted with Sa-SrtAΔN59 in the 
presence of two carbonyl moieties in the molecule, as removal of either group 
caused a complete loss of inhibitory activity [22]. Our indole-based compound C10
contains only one carbonyl group, which could be cause for less interaction with 
the Sa-SrtAΔN59 active site.
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FIGURE 3. Small molecules that showed moderate inhibition of Sp-SrtAΔN81 activity identifi ed 
by SOS approach, with the most potent molecule C10 depicted in the red box.
Next, steady-state kinetics were determined to evaluate the type of sortase A 
inhibition in the presence of diff erent concentrations of compound C10 (Figure 4B). 
Using a Michaelis-Menten model and the above mentioned fl uorometric assay, the 
Michaelis constant (Km) and the maximum rate (Vmax) were assessed. Both values 
changed with increasing inhibitor concentration: Km showed an increase, whereas 
Vmax values decreased. This result indicated a mixed type of inhibition, in which 
the inhibitor can bind to either the free enzyme (E) or the complex of enzyme and 
substrate (ES).
Binding affi  nity studies. In order to confi rm the binding and to characterize the 
interaction of compound C10 with Sp-SrtAΔN81, we used microscale thermophoresis 
(MST) [24]. The binding affi  nity Kd of compound C10 was determined to be 60 µM 
(Figure 5). Importantly, the MST results demonstrated that the C10 compound did 
not show autofl uorescence, nor did Sp-SrtAΔN81 aggregate in the presence of the 
small molecule. Thus, these results confi rm that C10 specifi cally interacts with Sp-
SrtAΔN81 and therefore minimize the chance that C10 belongs to the group of 
pan-assay interference compounds (PAINS) [25].
2
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FIGURE 4. The potency of sortase A inhibition in vitro in the presence of diff erent concentrations 
of compound C10. (A) Inhibition of purifi ed recombinant Sp-SrtAΔN81 with an IC50 of 10 µM. 
Specifi city of sortase A inhibition is shown by the lack of inhibition of Sa-SrtAΔN59. (B) Michae-
lis-Menten representation of Sp-SrtAΔN81 kinetics in the presence of diff erent concentrations 
of compound C10.
FIGURE 5. Binding of compound C10 to 50 nM purifi ed recombinant Sp-SrtAΔN81 with the 
dissociation constant of 60 µM.
Structure-activity relationship (SAR). To study and verify the importance of the 
substituents of C10 on the inhibition of Sp-SrtAΔN81 activity, three C10 analogues 
were synthesized (Scheme 1) and analyzed for their inhibitory activity (Figure 6).
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SCHEME 1. Synthesis of compounds 1-3. Reagents (R1 – R3) and conditions: a) NaH, DMF, 24 
h, RT, then HCl, FeCl3 and Zn, 1 h, 100°C, 30-32% yield; b) benzoylchloride, Et3N, dry CH2Cl2, 
N2, 18 h, RT, 50%.
The removal of the chlorine atom from the benzene ring in compound 1 (with respect 
to C10) led to a twofold reduction in the eff ectiveness of Sp-SrtAΔN81 inhibition. In 
contrast, exchange of the morpholino group of C10 for a piperidine ring resulted in 
a total loss of inhibitory properties for compound 2. A similar eff ect was observed 
for compound 3 when the amine group was benzyl-protected. To conclude, the 
modifi cation of C10 substituents contributing as donor-acceptor moieties hindered 
its interaction with Sp-SrtAΔN81.
FIGURE 6. SAR study of compound C10, illustrating the importance of the chemical substituents 
indicated with red circles.
Molecular modeling. The docking pose of the C10 molecule with the highest score 
demonstrates a binding in the active site as was initially hypothesized (Figure 7). In 
line with that, an overlay of the C10 binding poses with the highest scores illustrates 
equivalent docking poses (Supplementary Figure S5 and Table S2). Notably, two 
2
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positions that were shown to be crucial for the inhibition of Sp-SrtAΔN81 in the 
SAR studies were also predicted to be crucial in our model. The morpholino oxygen 
of the C10 compound interacts with the two amino acid residues His143 (3.11Å, 
-2.1 kcal/mol) and His142 (2.79Å, -0.9 kcal/mol), whereas the 2-amino functionality 
interacts with Val206 (2.98Å, -4.2 kcal/mol) (Figure 7B, Supplementary Table S3). 
These residues are located near the active site of the enzyme. This is in line with 
the mixed type inhibition in which inhibitors can bind close to the enzyme active 
site and thus aff ect both Km and Vmax constants.
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FIGURE 7. (A) Proposed binding mode of inhibitor C10 in the active site cleft of the enzyme. (B) 
2D model of the interaction of the C10 compound with Sp-SrtAΔN81.
CONCLUSIONS
It is of key importance to develop new approaches for the treatment of diff erent 
life-threatening diseases caused by strains of S. pyogenes, as resistance to currently 
used antibiotics is a signifi cant problem [3,26]. In this study, we employed a rational 
approach based on SOS combined with an in vitro fl uorometric assay to search for 
a potent Sp-SrtAΔN81 inhibitor. We identify the compound C10 with an IC50 value 
of 10 µM and a Kd of 60 μM. Our SAR studies clearly showed that the substituents 
of compound C10 are essential for the inhibitory properties towards Sp-SrtAΔN81. 
These SAR observations were confi rmed by our molecular modeling study, which 
proposed a binding mode of the C10 compound close to the active site of Sp-
SrtAΔN81. The information obtained by SAR and molecular modeling can be used 
for further improvement of the inhibitory properties of compound C10.
The prognosis is that by 2050, infections caused by antibiotic-resistant organisms 
will lead to the death of up to 10 million people per year [27]. We believe that our 
indole-based compounds can aid in the exploration of sortase inhibitors, which in 
turn can lead to the development of new anti-infective agents against S. pyogenes.
2





(2-amino-1H-indol-3-yl)(morpholino)methanone (1). The synthesis was adapted 
from a known procedure [28]. In short, 4 mL dry dimethylformamide (DMF), 
3-morpholino-3-oxopropanenitrile (R3) [29] (2.0 mmol, 1.0 equiv.) and NaH (60% 
dispersion in mineral oil, 2.2 mmol, 2.2 equiv.) were added to a 50 mL round-bottom 
flask equipped with a stirring bar. After 10 min, 2-fluoronitrobenzene (R1) (2.0 mmol, 
1.0 equiv.) was added, which led to a deep purple reaction mixture. The mixture was 
left stirring at room temperature for 24 h. Next day, 1.0 N HCl (4.0 mmol, 2.0 equiv.) 
was added, followed by FeCl3 (6.0 mmol, 3 equiv.) and Zn dust (20 mmol, 10 equiv.). 
The reaction mixture was heated to 100°C and left stirring for 1 h. The mixture 
was cooled afterwards and 20 mL of water was added. The crude reaction mixture 
was filtered and the sticky grey residue was washed with 25 mL of ethyl acetate. 
The ethyl acetate layer of the resulting filtrate was separated and the water layer 
was again extracted with ethyl acetate (2 x 20 mL). The combined organic extracts 
were washed with a saturated sodium bicarbonate solution (10 mL) and brine (10 
mL), dried with anhydrous magnesium sulfate and the solvent was removed under 
reduced pressure. The resulting crude product was dissolved in ether (10 mL), cooled 
to 0°C, and 2 M HCl in ether was added until no more formation of precipitate was 
observed. The precipitate was filtered and washed with cold ether to afford the 
product. Beige solid, yield 30%. 1H NMR (500 MHz, MeOH-d4) δ 7.40 - 7.37 (m, 2H), 
7.23 - 7.17 (m, 2H), 3.94 - 3.85 (m, 4H), 3.77 - 3.60 (m, 4H). 13C NMR (Chloroform-d, 126 
MHz) δ 170.42, 165.06, 142.26, 129.49, 126.61, 124.71, 123.52, 112.03, 66.39, 66.12, 
44.40, 42.75 ppm. HR-MS, calcd for C13H16N3O2 [M+H]+ 246.1237, found 246.1236 
(Supplementary Figure S2).
(2-amino-1H-indol-3-yl)(piperidin-1-yl)methanone (2). The synthesis was adapted 
from a known procedure [28]. In short, 4 mL dry dimethylformamide (DMF), 3-oxo-
3-(piperidin-1-yl)propanenitrile (R2) [29] (2.0 mmol, 1.0 equiv.) and NaH (60% 
dispersion in mineral oil, 2.2 mmol, 2.2 equiv.) were added to a 50 mL round-bottom 
flask equipped with a stirring bar. After 10 min, 2-fluoronitrobenzene (R1) (2.0 mmol, 
1.0 equiv.) was added, which led to a deep purple reaction mixture. The mixture was 
left stirring at room temperature for 24 h. Next day, 1.0 N HCl (4.0 mmol, 2.0 equiv.) 
was added, followed by FeCl3 (6.0 mmol, 3 equiv.) and Zn dust (20 mmol, 10 equiv.). 
The reaction mixture was heated to 100°C and left stirring for 1 h. The mixture 
was cooled afterwards and 20 mL of water was added. The crude reaction mixture 
was filtered and the sticky grey residue was washed with 25 mL of ethyl acetate. 
The ethyl acetate layer of the resulting filtrate was separated and the water layer 
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was again extracted with ethyl acetate (2 x 20 mL). The combined organic extracts 
were washed with a saturated sodium bicarbonate solution (10 mL) and brine (10 
mL), dried with anhydrous magnesium sulfate and the solvent was removed under 
reduced pressure. The resulting crude product was dissolved in ether (10 mL), cooled 
to 0°C, and 2 M HCl in ether was added until no more formation of precipitate was 
observed. The precipitate was fi ltered and washed with cold ether to aff ord the 
product. Beige solid, yield 32%. 1H NMR (500 MHz, DMSO-d6) δ 10.54 (s, 1H), 7.10 
(d, J = 8.5 Hz, 2H), 6.92 (t, J = 7.7 Hz, 1H), 6.83 (t, J = 7.7 Hz, 1H), 6.18 (br s, 2H), 3.39 
(t, J = 5.5 Hz, 4H), 1.61-1.57 (m, 2H), 1.55-1.50 (m, 4H). 13C NMR (126 MHz, DMSO-d6) 
δ 169.66, 152.42, 132.27, 126.74, 120.22, 118.57, 117.05, 110.09, 87.66, 46.50 (2C), 
26.38 (2C), 24.77. HR-MS, calcd for C14H18N3O [M+H]+ 244.1444, found 244.1443 
(Supplementary Figure S3).
N-(3-(morpholine-4-carbonyl)-1H-indol-2-yl)benzamide (3). Benzoylchloride chloride 
(1.5 mmol, 1.5 equiv.) was slowly added under a nitrogen atmosphere to a cooled 
(0°C) solution of compound 1 (1 mmol, 1.0 equiv.) and Et3N (210 μL, 1.5 mmol, 1.5 
equiv.) in dry CH2Cl2 (10 mL). After being stirred at room temperature for 18 h, a sat. 
sol. of NaHCO3 was added and the mixture was stirred for 15 minutes to destroy 
all remaining acyl chloride. Then, more CH2Cl2 was added and the layers where 
separated. The organic layer was washed with 1 N HCl (25 mL), a saturated solution 
of NaHCO3 (25 mL) and brine (25 mL), then dried over anhydrous magnesium sulfate 
and the solvent was removed under reduced pressure. The crude product was 
purifi ed with silica column chromatography with CH2Cl2:EtOAc 10:1 (v/v) as eluent. 
Yellow solid, yield 50%. 1H NMR (500 MHz, Chloroform-d) δ 7.73 – 7.69 (m, 2H), 
7.69 – 7.64 (m, 1H), 7.51 (m, 2H), 7.23 – 7.17 (m, 1H), 7.11 (m, 1H), 6.80 (br s, 2H), 6.72 
(m, 1H), 6.31 (m, 1H), 3.83 – 3.71 (m, 4H), 3.68 – 3.57 (m, 4H). 13C NMR (126 MHz, 
Chloroform-d) δ 192.49, 168.94, 152.67, 133.41, 131.53, 129.47, 129.27, 129.02, 128.86, 
127.13, 123.74, 119.97, 119.83, 117.76, 114.22, 99.98, 67.24 (2C), 46.21 (2C). HR-MS, 
calcd for C20H20N3O3 [M+H]+ 350.1499, found 350.1496 (Supplementary Figure S4).
Cloning, production and purifi cation of sortases. The DNA sequence encoding 
soluble, truncated sortase A (Sp-SrtAΔN81), Val82-Thr249, was kindly provided by 
Dr M.J. Banfi eld (Newcastle University, UK) and cloned into the BamHI and HindIII 
restriction sites of the expression vector pQIq [30]. The sortase A gene from S. 
aureus (Sa-SrtAΔN59) was cloned into the NdeI and BamHI restriction sites of 
the pET28a vector (Novagen, USA). The Escherichia coli BL21(DE3) strain (New 
England Biolabs, USA) was used for transformation of the plasmids encoding the 
recombinant sortases and subsequent protein production. The sortase enzymes 
2
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were each purified via their N-terminal M(R)GSH6-tags using Ni-NTA resin (Qiagen, 
Germany). The proteins were further purified by size exclusion chromatography 
in Tris-HCl buffer (50 mM, pH 7.5) containing 150 mM NaCl and 10% (v/v) glycerol.
Enzyme inhibition studies. A fluorometric assay was used to assess the inhibition 
of cleavage of the quenched substrate Abz-LPETA-Dap(Dnp) or Abz-LPETG-Dap(Dnp). 
(Bachem AG, Switzerland). Stock solutions of all inhibitor compounds were dissolved 
in dimethyl sulfoxide (DMSO) at a concentration of 10 mM and diluted with assay 
buffer consisting of 50 mM Tris-HCl, pH 7.5, and 150 mM NaCl and 100 mM CaCl2 
in case of Sa-SrtAΔN59, to a final concentration of 100 µM. Sortase enzymes 
were added to a final concentration of 2 µM and preincubated with the potential 
inhibitors for 10 min at RT. The reaction was initiated by the addition of internally 
quenched substrate at a final concentration of 20 µM. The fluorescence intensity was 
measured in 96-well black plates (Greiner Bio-One, Austria) using a FLUOstar Omega 
Microplate Reader (BMG Labtech, Germany) at the excitation wavelength of 317 nm 
and emission wavelength of 420 nm every minute for 2.5 h. The linear increase in 
fluorescence in the absence of inhibitor was determined as 100% activity of the 
enzyme and no fluorescence response in the absence of enzyme was observed. 
The threshold for selection of potent compounds was set to a reduction in enzyme 
activity of at least 50% compared to untreated controls.
The same fluorometric assay was used to determine the half maximal inhibitory 
concentration (IC50) values of selected compounds. Inhibitors were diluted with the 
assay buffer using a serial dilution to the concentrations ranging from 0.195 µM to 
100 µM. Data were analyzed using GraphPad Prism software; each data point was 
reported as the average of three measurements and their standard deviations.
Kinetics of sortase A. The fluorometric assay mentioned above was used for 
the evaluation of enzyme kinetics. The activity assay was performed in 50 mM 
Tris-HCl, pH 7.5, and 150 mM NaCl. Sp-SrtAΔN81 was diluted with the assay buffer 
to a final concentration of 2 µM. The Abz-LPETA-Dap(Dnp) concentrations were 
prepared in the range between 0 µM and 40 µM. The activity of the enzyme was 
measured in the presence of the inhibitor at the concentrations of 0 µM, 5 µM and 
10 µM. The progress of the reaction was monitored every minute for 2 h. The initial 
reaction velocities (V0) were plotted against the substrate concentrations. The Km 
and the Vmax values were calculated from the Michaelis-Menten equation using 
GraphPad Prism software. Each data point was reported as the average of three 
measurements.
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Microscale thermophoresis (MST). Binding studies between Sp-SrtAΔN81 and the 
C10 compound were performed with a Monolith NT.115 instrument using standard 
treated capillaries (NanoTemper Technologies, Germany). The His-tag of the target 
protein was labeled with an NT-647 fl uorescence dye (NanoTemper Technologies) 
according to the manufacturer’s instructions and the labeled protein was diluted to 
a concentration of  100 nM using the assay buff er consisting of phosphate-buff ered 
saline, pH 7.5 (137 mM NaCl, 2.7 mM KCl, 8 mM Na2HPO4 and 1.5 mM KH2PO4), 
with the addition of 0.05% (v/v) Tween-20. The conditions for LED and MST power 
were set to 40% and Medium, respectively. The compound C10 was diluted in the 
assay buff er without detergent to a concentration of 4 mM and a DMSO content 
of 4% (v/v). Equal amounts of labeled Sp-SrtAΔN81 were mixed in a 1:1 ratio with 
serial dilution of compound C10 starting from 2 mM. The Kd value was calculated 
from three replicate studies using NT analysis software (NanoTemper Technologies).
Molecular modeling. A docking study was performed to predict the binding 
mode of compound C10. This study was performed using the Molecular Operating 
Environment (MOE) software platform and the 3D structure of Sp-SrtAΔN81, 
PDB 3FN7. The experiments were performed with rescoring model 1 London dG 
(refi nement: forcefi eld) and rescoring 2: GBVI/WSA dG, followed by minimization 
energy (forcefi eld: MMFF94X; eps = r, cutoff  {8,10}).
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SUPPLEMENTARY TABLE S1. Structures and inhibition effi  ciency (in %, screening at 100 µM) of 
the compounds in the library. ND: not detected, signal outside the detection limit.
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LC-MS and NMR analysis of C10 and SAR compounds. The purity and mass of 
compound C10 were confi rmed by LC-MS analysis (Figure 1). Solvents and reagents 
for the synthesis of SAR compounds were purchased from Sigma-Aldrich and Acros 
chemicals, and were used without further purifi cation unless stated otherwise. 
Synthesis reactions were monitored by thin layer chromatography (TLC). Merck 
silica gel 60 F254 plates were used and spots were detected under UV light or after 
staining with potassium permanganate for the non UV-active compounds. 1H NMR 
(500 MHz) and 13C NMR (126 MHz) spectra were recorded with a Bruker Avance 
4-channel NMR Spectrometer with TXI probe. Chemical shifts were referenced 
to the residual proton and carbon signal of the deuterated solvent. The following 
abbreviations were used for spin multiplicity: s  =  singlet, br s  =  broad singlet, 
d = doublet, t = triplet, m = multiplet. Fourier Transform Mass Spectrometry (FTMS) 
of the SAR compounds was recorded on an Orbitrap XL Hybrid Ion Trap-Orbitrap 
Mass Spectrometer to give high-resolution mass spectra (HRMS).
FIGURE S1. The LC-MS analysis of compound C10.
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FIGURE S2. 1H NMR and 13C NMR spectra of compound 1 (2-amino-1H-indol-3-yl)(morpholino)
methanone.
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FIGURE S3. 1H NMR and 13C NMR spectra of compound 2 (2-amino-1H-indol-3-yl)(piperidin-1-yl)
methanone.
2
MagdaBinnenwerk.indd   33 19/02/2020   13:53:49
34
CHAPTER 2
FIGURE S4. 1H NMR and 13C NMR spectra of compound 3 N-(3-(morpholine-4-carbonyl)-1H-in-
dol-2-yl)benzamide.
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FIGURE S5. Overlay of C10’s binding poses with the highest score, using MOE software. The 
docking poses are: Blue binding pose 1, Green binding pose 2, Cyan binding pose 3.
TABLE S2. Detailed docking scores (MOE software) of the top binding poses of C10.




TABLE S3. Interactions of C10 with the receptor.
C10 Interaction Enzyme Distance [Å] E [kcal/mol]
N10 H-donor Val206 2.98 -4.2
O14 H-acceptor His142 2.79 -0.9
O14 H-acceptor His143 3.11 -2.1
2
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